Palvella Q2 net loss $9.5M; Phase 3 LM trial enrollment exceeded target by 25%

PALVELLA THERAPEUTICS, INC.

2025-Q2 EPS reported -$1.60 vs consensus -$0.76 ▼ miss (-111.8%)

Phase 3 SELVA enrolled 51 subjects (target 40); top-line results expected Q1 2026.
Cash $70.4M; expected to fund operations into second half of 2027.
Net loss $9.5M ($0.86/share) vs $4.4M ($2.47); R&D and G&A up due to trial costs.
Company plans to announce third QTORIN rapamycin indication and second platform candidate before year-end 2025.
Appointed Ashley Kline as Chief Commercial Officer; added to Russell 2000/3000 indexes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.